Estimation of molecular upper remission limit for monitoring minimal residual disease in peripheral blood of acute myeloid leukemia patients by WT1 expression

Experimental and Therapeutic Medicine

Volumn 3, Issue 1, 2012, Pages 129-133

  Polák, Jaroslav ^a   Hájková, Hana ^a   Maalaufová Soukupová, Jacqueline ^a   Marková, Jana ^a   Šálek, Cyril ^a   Schwarz, Jiří ^a   Haškovec, Cedrik ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

Author keywords

Acute myeloid leukemia; Minimal residual disease; Prognosis; Relapse; Wilm's tumor gene

Indexed keywords

ANTINEOPLASTIC AGENT; MOLECULAR MARKER; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BLOOD; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER PATIENT; CONTROLLED STUDY; FOLLOW UP; GENE EXPRESSION; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOCYTE; LIMIT OF DETECTION; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; PATIENT MONITORING; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS;

EID: 84855405450     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2011.363     Document Type: Article

References (27)

1. Cilloni D, Gottardi E, Fava M, et al: Usefulness of quantitative assessment of the WT1 gene transcript as a marker for minimal residual disease detection. Blood 102: 773-774, 2003.
2. Call KM, Glaser T, Ito CY, et al: Isolation and characterization of a zinc finger polypeptide gene at the human chromosome-11 Wilms' tumor locus. Cell 60: 509-520, 1990.
3. Scharnhorst V, van der Eb AJ and Jochemsen AG: WT1 proteins: functions in growth and differentiation. Gene 273: 141-161, 2001.
4. Menke AL and Schedl A: WT1 and glomerular function. Semin Cell Dev Biol 14: 233-240, 2003.
5. Silberstein GB, Van HK, Strickland P, Roberts CT Jr and Daniel CW: Altered expression of the WT1 Wilms tumor suppressor gene in human breast cancer. Proc Natl Acad Sci USA 94: 8132-8137, 1997.
6. Makrigiannakis A, Amin K, Coukos G, Tilly JL and Coutifaris C: Regulated expression and potential roles of p53 and Wilms' tumor suppressor gene (WT1) during follicular development in the human ovary. J Clin Endocrinol Metab 85: 449-459, 2000.
7. Nakatsuka S, Oji Y, Horiuchi T, et al: Immunohistochemical detection of WT1 protein in a variety of cancer cells. Mod Pathol 19: 804-814, 2006.
8. Miwa H, Beran M and Saunders GF: Expression of the Wilms-Tumor Gene (Wt1) in human leukemias. Leukemia 6: 405-409, 1992.
9. Menssen HD, Renkl HJ, Rodeck U, et al: Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. Leukemia 9: 1060-1067, 1995.
10. Inoue K, Ogawa H, Yamagami T, et al: Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels. Blood 88: 2267-2278, 1996.
11. Sugiyama H: Wilms tumor gene (WT1) as a new marker for the detection of minimal residual disease in leukemia. Leuk Lymphoma 30: 55-61, 1998.
12. Trka J, Kalinova M, Hrusak O, et al: Real-time quantitative PCR detection of WT1 gene expression in children with AML: prognostic significance, correlation with disease status and residual disease detection by flow cytometry. Leukemia 16: 1381-1389, 2002.
13. Ogawa H, Tamaki H, Ikegame K, et al: The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood 101: 1698-1704, 2003
14. Garg M, Moore H, Tobal K and Yin JAL: Prognostic significance of quantitative analysis of WT1 gene transcripts by competitive reverse transcription polymerase chain reaction in acute leukaemia. Br J Haematol 123: 49-59, 2003.
15. Ostergaard M, Olesen LH, Hasle H, Kjeldsen E and Hokland P: WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients - results from a single-centre study. Br J Haematol 125: 590-600, 2004.
16. Weisser M, Kern W, Rauhut S, Schoch C, Hiddemann W, Haferlach T and Schnittger S: Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia. Leukemia 19: 1416-1423, 2005.
17. Cilloni D, Gottardi E, De Micheli D, et al: Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 16: 2115-2121, 2002.
18. Osborne D, Frost L, Tobal K and Yin JAL: Elevated levels of WT1 transcripts in bone marrow harvests are associated with a high relapse risk in patients autografted for acute myeloid leukaemia. Bone Marrow Transplant 36: 67-70, 2005.
19. Candoni A, Tiribelli M, Toffoletti E, et al: Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia. Eur J Haematol 82: 61-68, 2009.
20. Cilloni D, Messa F, Arruga F, et al: Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy. Haematologica 93: 921-924, 2008.
21. Ommen HB, Nyvold CG, Braendstrup K, et al: Relapse prediction in acute myeloid leukaemia patients in complete remission using WT1 as a molecular marker: development of a mathematical model to predict time from molecular to clinical relapse and define optimal sampling intervals. Br J Haematol 141: 782-791, 2008.
22. Sakamoto Y, Mariya Y, Sasaki S, et al: WT1 mRNA level in peripheral blood is a sensitive biomarker for monitoring minimal residual disease in acute myeloid leukemia. Tohoku J Exp Med 219: 169-176, 2009.
23. Chomczynski P and Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159, 1987.
24. Polák J, Markova J, Schwarz J, Maaloufova J, Volkova Z, Cermak J and Haskovec C: [The use of quantitative assessment of Wilms tumour gene 1 for monitoring of residual disease in acute myeloid leukemia patients]. Cas Lek Cesk 145: 36-42, 2006.
25. Kreuzer KA, Saborowski A, Lupberger J, Appelt C, Na IK, Le Coutre P and Schmidt CA: Fluorescent 5'-exonuclease assay for the absolute quantification of Wilms' tumour gene (WT1) mRNA: implications for monitoring human leukaemias. Br J Haematol 114: 313-318, 2001.
26. Cilloni D, Renneville A, Hermitte F, et al: Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. J Clin Oncol 27: 5195-5201, 2009.
27. Gianfaldoni G, Mannelli F, Ponziani V, Longo G, Bencini S, Bosi A and Vannucchi AM: Early reduction of WT1 transcripts during induction chemotherapy predicts for longer disease free and overall survival in acute myeloid leukemia. Haematologica 95: 833-836, 2010.